Parmax Pharma Ltd manufactures bulk drugs, drugs intermediates, and specialty chemicalsBusiness Overview: Company used to do manufacturing bulk drugs and specialty chemicals but it discontinued its business activities for a few years. It deals in active pharmaceutical ingredients and Contract Manufacturing Operations. It plans to extend its activity to the...
Newspaper Publication for 32nd Annual general Meeting of the Company
Parmax Pharma's board has approved a preferential issue, allotting 31.37 lakh fully paid-up equity shares at Rs. 36.50 each to non-promoter investors, raising Rs. 11.45 Crore. Additionally, 21.45 lakh convertible warrants were allotted at Rs. 36.50 each to non-promoter investors, convertible into equity shares within 18 months. This capital raise...
Parmax Pharma has announced a significant shift in its ownership structure. Following an Open Offer and a Share Purchase Agreement, a new group of individuals will be classified as Promoters and members of the Promoter Group. The previous promoters, who sold 1,152,450 Equity Shares, representing 30.80% of the company's capital,...
Parmax Pharma has received 'In-Principle' approval from BSE for its planned preferential issue of securities. This significant step allows the company to issue 3.14 Cr equity shares and 2.15 Cr warrants, each convertible into an equal number of equity shares. The issue price for both shares and warrants is set...
Parmax Pharma Limited has announced the publication of its financial results for the quarter in The Financial Express. This follows a board meeting where the results were finalized. For retail investors, this means the latest snapshot of the company's financial performance is now publicly available. Accessing these published results allows...
